Certara, Inc. (CERT)
|Net Income (ttm)||-6.79M|
|Trading Day||January 19|
|Day's Range||36.70 - 38.59|
|52-Week Range||32.37 - 40.18|
STOCKHOLM, Dec. 17, 2020 /PRNewswire/ -- EQT is pleased to announce that on 10 December 2020, the EQT VII portfolio company Certara, Inc. ("Certara"), a global leader in biosimulation based on...
Certara Announces Closing of Its Upsized Initial Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
PRINCETON, N.J.--(BUSINESS WIRE)--Certara today announced that it closed its upsized initial public offering of 33,413,250 shares of common stock at $23.00 per share.
Hot initial public offerings aren't just for technology companies.
Drug Software Firm Certara Expands IPO to Raise $668 Million
Dec.11 -- Certara Inc., a maker of drug-development software, upsized its initial public offering and priced it above the marketed range to raise $668 million, adding to the red-hot week for U...
Certara CEO on strong IPO debut
CNBC's "Squawk Alley" team discusses Certara's IPO with CEO William Feehery.
Four companies increased the size of their deals.
PRINCETON, N.J.--(BUSINESS WIRE)--Certara today announced the pricing of its upsized initial public offering of 29,055,000 shares of its common stock at $23.00 per share.
The list of upcoming IPOs is starting to perk up. Here's a look at some interesting deals, including a variety of tech operators.
Certara has filed proposed terms for its $500 million U.S. IPO.
Certara, which provides biosimulation software and services used for drug development, filed on Wednesday with the SEC to raise up to $100 million in an initial public offering. However, t...
Certara, Inc. has filed to go public with an IPO on the NASDAQ.
Certara provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinincal and clinical research, regulatory submissions, and market access. It offers medicines to patients using biosimulation software and technology to transform drug discovery and development. The company also provides related technology-enabled services to guide its customers' new drugs through the regulatory submission process and into the market. Its technology-enabled services include mechanistic biosimulation, empiric... [Read more...]
|IPO Date |
Dec 11, 2020
William F. Feehery
|Stock Exchange |
|Ticker Symbol |
In 2019, Certara's revenue was $208.51 million, an increase of 27.36% compared to the previous year's $163.72 million. Losses were -$8.93 million, -73.16% less than in 2018.
According to 5 analysts, the average rating for Certara stock is "Buy." The 12-month stock price forecast is 36.00, which is a decrease of -3.23% from the latest price.